Premium
Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine
Author(s) -
He Guangsheng,
Zhang Xiang,
Wu Depei,
Sun Aining,
Wang Xiuli
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22865
Subject(s) - medicine , sirolimus , aplastic anemia , anti thymocyte globulin , refractory (planetary science) , immunosuppression , immune system , anemia , immunology , globulin , pharmacology , bone marrow , physics , astrobiology
Aplastic anemia (AA) is an immune‐mediated disease. Although most patients are responsive to immunosuppressive therapy (IST) with a combination of anti‐thymocyte globulin (ATG) and cyclosporine (CsA), some patients relapse or are refractory to IST. Sirolimus (rapamysin) inhibits the serine–threonine kinase mammalian target of rapamysin (mTOR), and blocks CsA‐resistant and calcium‐independent pathways late in the progression of the T‐cell cycle. We report two cases of AA which relapsed after CsA and ATG plus CsA, respectively. They achieved transfusion independence after retreatment with sirolimus in combination with a CsA. Pediatr Blood Cancer 2011;56:1133–1135. © 2011 Wiley‐Liss, Inc.